Search Results - "Miller, Randy"

Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization by Miller, Randy R, Madeira, Maria, Wood, Harold B, Geissler, Wayne M, Raab, Conrad E, Martin, Iain J

“…Lipophilicity has a dominant effect on many parameters that determine unbound drug exposure as well as drug potency. Despite this, analysis of a large body of…”
Get full text

Comparison of transmission FTIR, ATR, and DRIFT spectra: implications for assessment of bone bioapatite diagenesis by Beasley, Melanie M., Bartelink, Eric J., Taylor, Lacy, Miller, Randy M.

“…Evaluation of diagenesis in bioapatite samples is an important step for screening bone and tooth samples for stable isotope analysis to ensure in vivo…”
Get full text

Reproducible Large-Scale Isolation of Exosomes from Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Application in Acute Kidney Injury by Lee, Jun Ho, Ha, Dae Hyun, Go, Hyeon-Kyu, Youn, Jinkwon, Kim, Hyun-Keun, Jin, Richard C, Miller, Randy B, Kim, Do-Hyung, Cho, Byong Seung, Yi, Yong Weon

“…Acute kidney injury (AKI) is a fatal medical episode caused by sudden kidney damage or failure, leading to the death of patients within a few hours or days…”
Get full text

Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants by Talavera, Maria M, Bixler, Gary, Cozzi, Corin, Dail, James, Miller, Randy R, McClead, Jr, Richard, Reber, Kristina

“…To reduce the incidence of necrotizing enterocolitis (NEC) among very low birth weight (VLBW) infants admitted to 8 intensive care nurseries from a 2010…”
Get full text

Intraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell‐ and Tissue‐Based Therapies: Concise Review by Trivisonno, Angelo, Alexander, Robert W., Baldari, Silvia, Cohen, Steven R., Di Rocco, Giuliana, Gentile, Pietro, Magalon, Guy, Magalon, Jérémy, Miller, Randy B., Womack, Hayley, Toietta, Gabriele

“…The stromal vascular fraction (SVF) is a heterogeneous population of stem/stromal cells isolated from perivascular and extracellular matrix (ECM) of adipose…”
Get full text

Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury by Monroe, James J, Tanis, Keith Q, Podtelezhnikov, Alexei A, Nguyen, Truyen, Machotka, Sam V, Lynch, Donna, Evers, Raymond, Palamanda, Jairam, Miller, Randy R, Pippert, Todd, Cabalu, Tamara D, Johnson, Timothy E, Aslamkhan, Amy G, Kang, Wen, Tamburino, Alex M, Mitra, Kaushik, Agrawal, Nancy G B, Sistare, Frank D

“…Abstract Drug-induced liver injury is a major reason for drug candidate attrition from development, denied commercialization, market withdrawal, and restricted…”
Get full text

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir by Escobar, Patricia A, Sobol, Zhanna, Miller, Randy R, Ferry-Martin, Sandrine, Stermer, Angela, Jacob, Binod, Muniappa, Nagaraja, Sanchez, Rosa, Blanchard, Kerry T, Galijatovic-Idrizbegovic, Alema, Amin, Rupesh P, Troth, Sean P

“…Molnupiravir is registered or authorized in several countries as a 5-day oral COVID-19 treatment for adults. Molnupiravir is a prodrug of the antiviral…”
Get full text

Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit by Lewald, Zachery S., Prusakov, Pavel, Magers, Jacqueline K., Kielt, Matthew J., de Alba Romero, Concepción, White, Natalie O., Miller, Randy R., Moraille, Richard, Theile, Anthony R., Sánchez, Pablo J.

“…Objective To determine the adherence and safety outcomes of a 5-day antibiotic course with a “time-out” for treatment of “blood culture-negative” pneumonia in…”
Get full text

Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus by Madani, Abdeldjalil, Negatu, Dereje A., El Marrouni, Abdellatif, Miller, Randy R., Boyce, Christopher W., Murgolo, Nicholas, Bungard, Christopher J., Zimmerman, Matthew D., Dartois, Véronique, Gengenbacher, Martin, Olsen, David B., Dick, Thomas

“…Tricyclic pyrrolopyrimidines (TPPs) are a new class of antibacterials inhibiting the ATPase of DNA gyrase. TPP8, a representative of this class, is active…”
Get full text

Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU by Sánchez, Pablo J., Prusakov, Pavel, de Alba Romero, Concepción, Zamora-Flores, Elena, Reyes Escamilla, María Camila, White, Natalie O., Miller, Randy R., Moraille, Richard, Theile, Anthony R., Magers, Jacqueline K.

“…Objective On 2/2019, the Neonatal Antimicrobial Stewardship Program at Nationwide Children’s Hospital recommended reducing empirical antibiotic therapy for…”
Get full text

Molnupiravir: Mechanism of action, clinical, and translational science by Maas, Brian M., Strizki, Julie, Miller, Randy R., Kumar, Sushma, Brown, Michelle, Johnson, Matthew G., Cheng, Mickie, De Anda, Carisa, Rizk, Matthew L., Stone, Julie A.

“…Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken…”
Get full text

Cerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat Acinetobacter baumannii : From Screening Impurity to In Vivo Efficacy by Skudlarek, Jason W, Cooke, Andrew J, Mitchell, Helen J, Babaoglu, Kerim, Shaw, Anthony W, Tong, Ling, Nomland, Ashley B, Labroli, Marc, Sha, Deyou, Mulhearn, James J, Wu, Chengwei, Li, Sarah W, Beshore, Douglas C, Hughes, Jonathan M E, Jouffroy, Matthieu, Wang, Hao, Balibar, Carl J, Painter, Ronald E, Shen, Pamela, Lange, Henry S, Ishchenko, Andrii, Chen, Yun-Ting, Klein, Daniel J, Tracy, Rodger W, Miller, Randy R, Cabalu, Tamara D, Wu, Zhe, Leithead, Andrew, Scapin, Giovanna, Hruza, Alan W, Dzhekieva, Liudmila, Bukhtiyarova, Marina, Homsher, Michelle F, Xu, Min, Bahnck-Teets, Carolyn, McKenney, David, Buevich, Alexei V, Liu, Jian, Zhang, Li-Kang, Meng, Tao, Kelly, Terri, DiNunzio, Edward, Soisson, Stephen, Cheng, Robert K Y, Hennig, Michael, Raheem, Izzat, Walker, Scott S

“…, a commonly multidrug-resistant Gram-negative bacterium responsible for large numbers of bloodstream and lung infections worldwide, is increasingly difficult…”
Get full text

Discovery of N‑[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia by Debenham, John S, Madsen-Duggan, Christina, Clements, Matthew J, Walsh, Thomas F, Kuethe, Jeffrey T, Reibarkh, Mikhail, Salowe, Scott P, Sonatore, Lisa M, Hajdu, Richard, Milligan, James A, Visco, Denise M, Zhou, Dan, Lingham, Russell B, Stickens, Dominique, DeMartino, Julie A, Tong, Xinchun, Wolff, Michael, Pang, Jianmei, Miller, Randy R, Sherer, Edward C, Hale, Jeffrey J

“…The discovery of novel 4-hydroxy-2-(heterocyclic)­pyrimidine-5-carboxamide inhibitors of hypoxia-inducible factor (HIF) prolyl hydroxylases (PHD) is described…”
Get full text

P223 - PPB: Considerations for safety studies and data interpretation by Pajkovic, Natasa, Kuo, Yuhsin, Bennet, Amrith, Gonzalez, Raymond, Bernard, Laïla, Poignant, Frédéric, Miller, Randy

Get full text

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder by Edmondson, Scott D, Zhu, Cheng, Kar, Nam Fung, Di Salvo, Jerry, Nagabukuro, Hiroshi, Sacre-Salem, Beatrice, Dingley, Karen, Berger, Richard, Goble, Stephen D, Morriello, Gregori, Harper, Bart, Moyes, Christopher R, Shen, Dong-Ming, Wang, Liping, Ball, Richard, Fitzmaurice, Aileen, Frenkl, Tara, Gichuru, Loise N, Ha, Sookhee, Hurley, Amanda L, Jochnowitz, Nina, Levorse, Dorothy, Mistry, Shruty, Miller, Randy R, Ormes, James, Salituro, Gino M, Sanfiz, Anthony, Stevenson, Andra S, Villa, Katherine, Zamlynny, Beata, Green, Stuart, Struthers, Mary, Weber, Ann E

“…The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical…”
Get full text

A trial comparing continuous positive airway pressure (CPAP) devices in preterm infants by Backes, Carl H., Cooper, Jennifer N., Notestine, Jennifer L., Alfred, Crystal M., Ball, Molly K., Rivera, Brian K., Lamp, Jane M., Marzec, Laura, Stenger, Michael R., Moallem, Mohannad, Miller, Randy R., Naik, Apurwa, Beer, Lindsey J., Howard, Christopher R., Welty, Stephen E., Peter Richardson, C., Hillman, Noah H., Zupancic, John A. F., Stanberry, Larissa I., Hansen, Thomas N., Smith, Charles V.

“…Objective To test the hypothesis that infants born <30 weeks’ gestation supported by Seattle-PAP will have lower rates of continuous positive airway pressure…”
Get full text

Evaluating the efficacy of Seattle-PAP for the respiratory support of premature neonates: study protocol for a randomized controlled trial by Backes, Carl H, Notestine, Jennifer L, Lamp, Jane M, Balough, Jeanne C, Notestine, Allison M, Alfred, Crystal M, Kern, Juli M, Stenger, Michael R, Rivera, Brian K, Moallem, Mohannad, Miller, Randy R, Naik, Apurwa, Cooper, Jennifer N, Howard, Christopher R, Welty, Stephen E, Hillman, Noah H, Zupancic, John A F, Stanberry, Larissa I, Hansen, Thomas N, Smith, Charles V

“…At birth, the majority of neonates born at <30 weeks of gestation require respiratory support to facilitate transition and ensure adequate gas exchange…”
Get full text

Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii by Wang, Hao, Ishchenko, Andrii, Skudlarek, Jason, Shen, Pamela, Dzhekieva, Liudmila, Painter, Ronald E., Chen, Yun-Ting, Bukhtiyarova, Marina, Leithead, Andrew, Tracy, Rodger, Babaoglu, Kerim, Bahnck-Teets, Carolyn, Buevich, Alexei, Cabalu, Tamara D., Labroli, Marc, Lange, Henry, Lei, Ying, Li, Wei, Liu, Jian, Mann, Paul A., Meng, Tao, Mitchell, Helen J., Mulhearn, James, Scapin, Giovanna, Sha, Deyou, Shaw, Anthony W., Si, Qian, Tong, Ling, Wu, Chengwei, Wu, Zhe, Xiao, Jing Chen, Xu, Min, Zhang, Li-Kang, McKenney, David, Miller, Randy R., Black, Todd A., Cooke, Andrew, Balibar, Carl J., Klein, Daniel J., Raheem, Izzat, Walker, Scott S.

“…Carbapenem-resistant Acinetobacter baumannii infections have limited treatment options. Synthesis, transport and placement of lipopolysaccharide or…”
Get full text

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development by van den Berg, Paul, Gao, Wei, Ahsman, Maurice J., Arrington, Leticia, Kesisoglou, Filippos, Miller, Randy, Post, Teun M., Rizk, Matthew L.

“…Uprifosbuvir is a uridine nucleoside monophosphate prodrug inhibitor of the hepatitis C virus NS5B RNA polymerase. To quantitatively elucidate key metabolic…”
Get full text

Experimental and Theoretical Investigations of the Bromination of Phenols with β and γ Aliphatic Substituents, including Rings by Zhang, Jinsong, Chang, Xiao, Bowman, Erich C, Holt, Carter J, Lodewyk, Michael W, Miller, Randy M, Xia, Guangming

“…Bromination reactions of substituted and ring fused phenols were studied by both experiment (t-BuNH-Br) and computation (density functional theory). The…”
Get full text